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Background: MicroRNA-133b (miR-133b), which is a muscle-specific microRNA, has been reported to be downregulated
in human colorectal carcinoma (CRC) when compared to adjacent non-tumor tissue. However, its diagnostic value and
role in CRC have yet to be described. CXC chemokine receptor-4 (CXCR4), which participates in multiple cell processes
such as cell invasion-related signaling pathways, was predicted to be a potential target of miR-133b. The aim of this
study was to investigate the associations and functions of miR-133b and CXCR4 in CRC initiation and invasion.
Methods: Mature miR-133b and CXCR4 expression levels were detected in 31 tumor samples and their adjacent,
non-tumor tissues from patients with CRC, as well as in 6 CRC cell lines, using real-time quantitative RT-PCR (qRT-PCR).
Luciferase reporter assays and Western blots were used to validate CXCR4 as a putative target gene of miR-133b.
Regulation of CXCR4 expression by miR-133b was assessed using qRT-PCR and Western blot analysis, and the effects of
exogenous miR-133b and CXCR4 on cell invasion and migration were evaluated in vitro using the SW-480 and SW-620
CRC cell lines.
Results: A significant downregulation of miR-133b was observed in 93.55% of CRC tissues, and the expression of
miR-133b was much lower in metastatic tumors (stage C and D, stratified by the Modified Dukes Staging System)
than in primary tumors (stage A and B). In contrast, CXCR4 protein expression significantly increased in 52.63% of
CRC samples, and increased CXCR4 expression in CRC was associated with advanced tumor stage. CXCR4 was
shown to be a direct target of miR-133b by luciferase reporter assays, and transfection of miR-133b mimics inhibited
invasion and stimulated apoptosis of SW-480 and SW-620 CRC cells.
Conclusions: Our study demonstrated that downregulated miR-133b contributed to increased cell invasion and
migration in CRC by negatively regulating CXCR4. These findings may be significant for the development of therapy
target for CRC.
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Colorectal cancer (CRC) is the third most common can-
cer in males and the second most common cancer in
females worldwide and has high incidence and mortality
rates [1]. The number who are affected continues to rise,
especially in most Asian countries [2]. Despite gradually
improved therapeutic schedules, post-operative recurrence
and metastasis remain the two most challenging problems
for prolonging patient survival time after surgery. Thus, it
is necessary to understand the precise molecular mecha-
nisms that modulate malignant transformation.
MicroRNAs (miRNAs), which are a class of endogen-
ous, single-stranded RNA molecules of 20–25 nucleotides
in length [3], have emerged as critical regulators of car-
cinogenesis and tumor progression over the last decade
[4,5] and are likely to be involved in widespread biological
functions, such as cell proliferation, apoptosis, invasion,
angiogenesis and metastasis [5,6]. In addition, reports have
increasingly shown the potential of using miRNAs as
novel diagnostic markers and therapeutic targets [4,7-9].
miR-133b, which is a miRNA commonly recognized
as a muscle-specific molecule, participates in myoblast
differentiation [10,11] and myogenic-related diseases [12,13].
Recent studies showed that miR-133b also plays a cru-
cial role in the malignant progression of non-muscle-
related diseases [14-16] such as cancer [14-19]. For
example, Bandrés et al. [14] revealed the deregulation
of miR-133b alongside 12 deregulated miRNAs in 15 CRC
cell lines and 6 paired human CRC specimens. Hu et al.
[17] uncovered receptor tyrosine kinase METas one target
of miR-133b in CRC and demonstrated its involvement in
cell proliferation and apoptosis. Another study showed
that the downregulation of miR-133b in CRC tissues,
when compared to adjacent non-tumor tissues, was linked
to poor survival [5]. However, it remains undeterminedFigure 1 Expression of miR-133b was downregulated in CRC. (A-B) m
from 31 patients. Data were analyzed in groups, and all data were normaliz
tumors; M, metastasis tumors. (C) ROC of miR-133b.how miR-133b functions in CRC pathogenesis and pro-
gression, especially in CRC invasion and metastasis.
The CXC chemokine receptor 4 (CXCR4) belongs to
the G protein-coupled receptor (GPCRs) family [20,21].
Through a specific interaction with its ligand CXCL12
(stromal cell-derived factor-1, SDF-1) [22], CXCR4 par-
ticipates in the development of primary tumors and me-
tastases [23]. The dysregulated expression of CXCR4 was
detected in several human cancers that included melan-
oma [24], breast [25], pancreatic [26] and CRC [24]. In
particular, as a versatile factor in human CRC, CXCR4
influences aspects such as proliferation [27], migration
and invasion [27,28]. Understanding the regulation net-
work of CXCR4 would give us a deeper insight into the
mechanisms underlying CRC metastasis and help in the
development of new therapeutic regimens.
In this study, we found that CXCR4 was a direct target
of miR-133b in colorectal cancer. We also demonstrated
that miR-133b contributed to increased cell invasion by
negatively regulating CXCR4 activity in CRC carcinogen-
esis and progression.
Results
Decreased expression of miR-133b in human CRC showed
significant diagnostic potential
To investigate whether the expression level of this muscle-
specific miRNA was associated with disease progression,
we first conducted qRT-PCR analyses to detect miR-133b
expression in 31 human CRC tissues and their 19 counter-
parts from non-neoplastic adjacent tissues. As shown in
Figure 1A, a significant downregulation of miR-133b
was noted in 29 of the 31 tumor samples (93.55%) when
compared to non-neoplastic tissues (p < 0.001), and the
expression of miR-133b in metastatic tumor tissues was
much lower than that in the primary tumors (p < 0.05,iR-133b expression was measured by qRT-PCR in clinical CRC tissues
ed to U6 snRNA. T, tumor tissue; N, adjacent normal tissues. P, primary
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of miR-133b might be involved in human CRC initiation
and progression.
We then examined the sensitivity and specificity of
miR-133b. A receiver operating characteristic (ROC) curve
analysis was performed using the relative expression of
miR-133b, and the associated area under the curve (AUC)
was used to confirm the diagnostic potency of the miRNA.
As shown in Figure 1C, the AUC of miR-133b reached
0.8081 [95% confidence interval (CI): 0.6857-0.9306,
P < 0.001], with a cut-off point of 77.42% sensitivity and
78.95% specificity. These results suggest that miR-133b
can discriminate between CCA tissues and their paired
adjacent normal tissues.
CXCR4 was a direct target of miR-133b
To gain insight into the biological role of miR-133b that
underlies disease pathogenesis, we further investigated
its downstream targets. Three bioinformatics algorithms,
TargetScan [29], miRBase Target [30] and StarBase [31],
were applied to search for the potential targets of miR-
133b, and a number of potential targets were predicted.
Among the predicted targets, CXCR4 was the most
interesting. CXCR4 has been reported to be widely
expressed and to exert large-scale effects in cancer cells
by participating in multiple cellular processes, including
cell invasion-related signaling [32]. It has also been re-
ported that upregulation of CXCR4 was found in CRC
patients and increased the risk of recurrence and poor
survival from CRC [33].
We then validated the binding of miR-133b to the
3′UTR of CXCR4 using a luciferase reporter assay, and
miR-139 served as a positive control [34]. The detailed
information used for the dual luciferase reporter assays
is shown in Figure 2A. Exogenous expression of miR-
133b, which was induced by introducing the miR-133b
duplex into HEK-293T cells using Lipofectamine 2000,
suppressed the activity of a Renilla luciferase construct
containing the miR-133b MRE (miRNA response re-
gion) of human CXCR4 at its 3′ end by approximately
42.7% (P < 0.01) (Figure 2B). Similarly, the activity of a
luciferase construct containing the entire 3′UTR of
CXCR4 was suppressed by approximately 51.6% of the
Renilla luciferase activity (P < 0.01) by ectopic miR-133b
expression (Figure 2C). Suppression of luciferase activ-
ity was abolished when a full mismatch mutation was
introduced into the miR-133b–MRE within the CXCR4
3′UTR (Figure 2B). These data indicated that the pre-
dicted MRE was critical for the direct and specific bind-
ing of miR-133b to the CXCR4 mRNA.
To further confirm that the CXCR4 protein is sup-
pressed by miR-133b, we then overexpressed and knocked
down miR-133b in colorectal cancer cell lines. miR-133b
was first detected in six CRC cell lines (SW-480, SW-620,HCT-116, HCT-15, RKO and Caco-2). Notably, the
miR-133b expression level in SW-480 was considerably
higher than in the other five cell lines, while the SW-620
cell line had the lowest level of expression (Figure 2D and
Figure 3A). The SW-480 and SW-620 cell lines were
derived from the same CRC patient but at different stages
[35]. SW-480 originated from a primary tumor, and
SW-620 was from a metastatic lymph node. The lower
expression level of miR-133b in SW-620 than in SW-480
was consistent with the expression pattern in clinical
samples. Thus, in subsequent experiments, we primarily
used these two cell lines for functional studies: SW-620
was used for the gain-of-function study due to its con-
siderably lower endogenous miR-133b level, and SW-480
was used for the loss-of-function study due to its higher
level of miR-133b expression. As shown in Figure 2E,
when SW-620 cells were transfected with the miR-133b
mimics, the CXCR4 protein was significantly reduced.
Alternatively, when the cells were transfected with the
miR-133b inhibitor, CXCR4 protein expression increased
in SW-480. The efficiency of siCXCR4 was verified using
Western blotting (Figure 2E), and successful exogenous
molecular transfection and efficiency was confirmed by
qRT-PCR (Additional file 1: Figure S1A). These results
indicated that CXCR4 is a bona fide target of miR-133b.The inverse correlation between miR-133b and CXCR4 in
CRC cell lines and clinical samples
To further validate the correlation between miR-133b and
CXCR4, we then detected the expression levels of the
CXCR4 protein in the six human CRC cell lines and in
the clinical samples that were previously used for miR-
133b detection. Intriguingly, the CXCR4 protein expres-
sion level in SW-620 was shown to be much higher than
in SW-480 (Figure 3A) and was negatively coexpressed
with the expression of miR-133b (Figure 3A). These
results supported the hypothesis that CXCR4 is repressed
by miR-133b. We then investigated the coexpression pattern
between miR-133b and CXCR4 in the clinical samples. A
panel of clinical samples that included CRC tissues and their
corresponding adjacent non-neoplastic tissues was used.
Correlation analysis showed a significant relationship
between these factors (Spearman r = −0.2840; p = 0.0456),
and the results are shown in Figure 3B. The expression
levels of miR-133b were significantly lower in CRC tumor
tissues when compared to the NT group (Figure 1A). Con-
versely, the levels of CXCR4 protein were elevated in
52.63% (10/19) of the tumors when compared to their cor-
responding non-tumor tissues (Additional file 2: Figure S2).
The remainder of the tested samples showed no signifi-
cant differences between the two groups. Thus, a negative
correlation exists between the level of miR-133b and the
level of CXCR4 protein in CRC tumors.
Figure 2 CXCR4 is a direct target of miR-133b. (A) Schematic of the luciferase reporter assay used to validate the interaction between miR-133b
and the 3′UTR of CXCR4. Grey font indicates the ‘seed’ regions. The MRE CXCR4 3′UTR of wild, full mutant and full length were separately inserted into
a psiCHECK-2 vector downstream from the Renilla luciferase gene. (B-C) Dual luciferase reporter assays performed using the 59 nt flanking the MRE, full
mutation in the MRE (B) and the entire 3′UTR of CXCR4 (C). (D) miR-133b expression was measured using qRT-PCR in SW-480 and SW-620 human
CRC cell lines and normalized to U6 snRNA expression. (E) miR-133b suppressed CXCR4 expression in CRC cells. CXCR4 protein expression of CRC cells
transfected with miR-133b mimic, miR-133 inhibitor, siCXCR4 or a negative control normalized to GAPDH expression. Data are shown as the mean ± SD
from three independent assays. *P < 0.05, ** P < 0.01 compared to controls.
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and apoptosis by modulating CXCR4 levels
To investigate whether miR-133b functions as a tumor
suppressor by promoting cell apoptosis and impairing
proliferation, we performed overexpression and knock-
down studies to characterize the effect of miR-133b onCRC proliferation using the miR-133b mimics, miR-133b
inhibitor and siCXCR4 in SW-480 and SW-620 cells. The
transfection efficiencies of siCXCR4 in both cell lines
are shown in Additional file 1: Figure S1. The introduction
of miR-133b or knocking down CXCR4 with siCXCR4
caused a remarkable inhibition of cell proliferation in
Figure 3 The inverse correlation between miR-133b and CXCR4 in CRC cells and clinical samples. (A) CXCR4 protein expression in CRC
cells was detected using Western blot analysis normalized to GAPDH expression. Expression of miR-133b and the CXCR4 protein level was
inversely correlated. (B) The inverse correlation between miR-133b and CXCR4 in CRC tissues. miR-133b and CXCR4 mRNA were measured
using qRT-PCR. Correlation analysis showed a significant relationship between these factors (Spearman r = −0.2840; P = 0.0456).
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trols (p < 0.05 at 96 h) (Additional file 3: Figure S3A and
B). In contrast, when miR-133b activity was impeded by
the miR-133b inhibitor, the cells presented strengthened
proliferation ability (p < 0.05 at 96 h) (Additional file 3:
Figure S3C and D).
A colony formation assay was performed to further
substantiate this observation. The miR-133b- and siCXCR4-
transfected cells formed fewer colonies than the control-
transfected cells in SW-480 and SW-620 cells within 12 days,
while the opposite effect was observed in cells transfected
with the miR-133b inhibitor (Figure 4A and Additional
file 4: Figure S4; p < 0.01). These results suggested that
miR-133b could inhibit the growth of SW-480 and SW-
620 cells through the targeting of CXCR4.
Proliferation and apoptosis are two classic but cru-
cial aspects of nearly all acquired diseases. Accordingly,
fluorescence-activated cell sorting (FACS) analysis was
used to assess whether miR-133b contributed to apoptosis
in CRC cells. Apoptosis was measured after transfecting
miR-133b and siCXCR4 into SW-480 and SW-620 cells
for 48 hours, and this was followed by a 24-hour exposure
to cisplatin at an appropriate concentration, as previously
described [36] (The IC50 results are not shown). The
results revealed a significant increase in apoptosis of
SW-620 cells transfected with miR-133b mimics com-
pared to the control transfected cells (the percentage of
apoptotic cells increased from 21.31% to 88.37%; Figure 4B;
p < 0.001).
The converse effect was observed in cells transfected
with miR-133b inhibitor (Figure 4C). As observed in
Figure 4C, the apoptotic rate in SW-480 cells trans-
fected with the miR-133b inhibitor dropped from 18.77%
to 10.67% (p < 0.01), and this apoptosis-promoting effectof siCXCR4 was corroborated in both cell lines. In
SW-480 cells, apoptosis increased from 29.13% to 55.81%
(p < 0.001), and in SW-620 cells, it increased from 20.69%
to 50.09% (Figure 4D, p < 0.001). The apoptosis result
was further confirmed using fluorescence microscopy,
in which the pretreatment of cells was similar to that by
flow cytometry analysis (Additional file 5: Figure S5).
These results indicate that overexpression of miR-133b
induced an aggravated apoptosis rate and an impaired
proliferation of CRC cells.
Forced expression of exogenous miR-133b decreases CRC
cell invasion and migration in vitro
The lower expression level of miR-133b in advanced CRC
SW-620 cells implied that miR-133b might contribute
to the metastatic features of CRC. We postulated that
ectopic expression of miR-133b in CRC cells could im-
pede the migratory and invasive abilities of CRC cells.
To confirm this speculation, miR-133b mimics were
transiently introduced into the cells for 36 hours. The
cells were then starved for 12 hours, and the migration
assays were performed. As expected, exogenous expres-
sion of miR-133b and siCXCR4 substantially impeded
the migratory ability of CRC cells, as indicated by the
decreased number of migrated cells (Figure 5A). A simi-
lar result was also observed using the cell invasion assay
that was counted using a microscope (Figure 5B). We
also transiently transfected miR-133b inhibitors into
the cells. As shown in Figure 5A and 5B, inhibition of
miR-133b significantly increased cell migration and in-
vasion, especially in SW-480 cells, which had relatively
higher endogenous miR-133b expression.
We used a scratch wound healing assay to further
demonstrate the function of miR-133b in migration potency.
Figure 4 (See legend on next page.)
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Figure 4 The effect of the oligonucleotides on proliferation and apoptosis of CRC cells. (A) Colony formation assay performed for SW-480
cells. The number of colonies on the entire plate was counted. (B-D) Induced apoptosis in CRC cells. After 48 h of incubation in the presence of
controls or siCXCR4 and following 24-h exposure to cisplatin, all of the cells were stained with Annexin V–FITC and propidium iodide (PI) followed
by flow cytometric analysis. Data are expressed as the mean ± SD of three independent experiments. (B) miR-133b mimic strengthened apoptosis
in CRC cells. (C) The miR-133b inhibitor suppressed apoptosis in CRC cells. (D) siCXCR4 increased apoptosis in CRC cells.
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inhibited wound closure in both cell lines compared to
the control (Figure 5C). In contrast, when transfected
with the miR-133b inhibitor, the speed of wound closure
was increased. Our results suggest that miR-133b sup-
presses CRC metastasis by regulating the migratory
and invasive abilities of CRC cells through CXCR4. To
further reveal the potential signaling pathway that underliesFigure 5 miR-133b regulates motility of CRC cells. (A) The transwell
SW-480 and SW-620 cells transfected with miR-133b mimic, miR-133b inhibi
invaded or migrated to the lower upside were counted using a microscope.
motilities of SW-480 and SW-620 cells transfected with the miR-133b mimic,
were observed at 0, 24 and 48 hours following wounding by a pipette tip. Othe miR-133b/CXCR4 interaction, we investigate the expres-
sion of the CXCR4 downstream genes vascular endothe-
lial growth factor (VEGF) and matrix metalloproteinase-9
(MMP-9) [37,38]. The results showed that their expres-
sions were affected by the miR-133b mimics and in-
hibitor in the SW-480 and SW-620 cell lines (Figure 6),
that miR-133b regulates CXCR4 to affect its classic under-
lying pathway.invasion and a migration assays were used to detect the motility of
tor, siCXCR4 or their corresponding negative controls. (B) The cells that
Original magnification: 200×. (C) Using a wound healing assay, the cell
miR-133b inhibitor, siCXCR4 or their corresponding negative controls
riginal magnification: 100×.
Figure 6 qRT-PCR was used to detect the expression of the VEGF and MMP-9 genes in the SW-480 and SW-620 cell lines transfected
with the miR-133b mimics, miR-133b inhibitor or CXCR4 siRNA.
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CRC is one of the most common and lethal cancers and
has a high relapse rate. Therefore, there is a strong need
to develop novel, prognostic factors and therapeutic
strategies. The outcome of CRC patients is determined
primarily by the presence or absence of metastases. Thus,
insight into the molecular mechanisms underlying the
precise molecular mechanisms that modulate malignant
transformation is required. Previous studies have shown
that aberrant expression of miR-133b was found in CRC
cancer tissues [14,17] and that overexpression of miR-
133b induced apoptosis and G1 cell-cycle arrest in CRC
cells [17]. Furthermore, miR-133b has reportedly been
shown to be involved in the invasion of several other
cancers. For instance, miR-133b was found to be down-
regulated in non-small cell lung cancer and modulate
apoptosis and invasion [16], and overexpression of miR-
133b has been shown to inhibit cell invasion activity
in esophageal squamous cell carcinoma [19]. However,
the relationship between miR-133b expression and cell
metastases in CRC has yet to be demonstrated.
In the present study, we investigated the expression
patterns of miR-133b in CRC clinical samples and iden-
tified low miR-133b expression as a valid factor associated
with advanced tumor stages. Further functional analysis
revealed the involvement of miR-133b in the progression
of human CRC, and transfection of miR-133b into two
CRC cell lines, SW-480 and SW-620, significantly de-
creased tumor cell migration and invasion in vitro.
These data provide the potential of miR-133b to serve
as a molecular target for CRC therapy, especially for
tumors with high degrees of metastasis. It is also worth
noting that the outcome of CRC patients is highly relevantto the extent of local invasion; therefore, the metastases-
related miR-133b might provide tumor progression and
prognostic information in CRC patients who would need
to be experimentally validated prospectively.
We revealed the involvement of miR-133b in the pro-
gression of human CRC via the regulation of CXCR4
expression. A significant correlation was also found be-
tween miR-133b and CXCR4 protein expression in tumor
samples. The activation of CXCR4, a G protein-coupled
receptor for CXCL12, induced tumor invasion and/or
survival of cancer cells. CXCR4 has also been reported
to be involved in a number of processes related to the
immune system [39], the nervous system [40], angiogen-
esis [41], the hemopoietic system [42] and carcinogenesis
[28,43-46]. Therefore, it is a key receptor in the crosstalk
between tumor cells and their microenvironment.
Our results demonstrated that the miR-133b/CXCR4
pair is involved in tumor growth and tumor cell apoptosis
and controls cell migration and invasion. Intriguingly,
CXCR4 has been regarded as an impressive anticancer
target that suppresses the outgrowth of metastases in
CRC [28]. Moreover, previous reports have shown that
the small non-peptide CXCR4 inhibitor ADM3100 ef-
fectively inhibited the invasion and metastasis activity
of CRC [47], which strongly shows the potential of
CXCR4 as a therapy target. Furthermore, we found that
the miR-133b/CXCR4 interaction influenced CRC pro-
gression through modifying the VEGF and MMP-9 genes,
both of which play significant roles in CRC, especially in
migration and invasion [48,49]. More importantly, we
determined the downstream molecules of the miR-133b/
CXCR4 interaction as was done in previous research on
CXCR4 in CRC [37]. This finding implies that miR-133b




Age at diagnosis Dukes classification Metastasis
situation
1 F* 42y C* -*
2 F 40y B* -
3 M* 51y B -
4 M 63y C LN*
5 M 62y C LN
6 M 69y C -
7 M 33y C -
8 F 64y C -
9 F 83y C LN
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which highlights the potential of this miRNA to be used
as a CXCR4 inhibitor in CRC treatment. Taken together,
our research provides an alternative strategy for develop-
ing miRNA-based therapy via CXCR4 targeting in CRC,
and this is considered more security for the natural and
endogenous of miRNAs.
In conclusion, our current findings provide the first
glimpse of the functional role of miR-133b in CRC car-
cinogenesis and progression through the negative regula-
tion of CXCR4. We also identified the crucial role of
this miRNA in tumor cell invasion. These results indi-
cate that miR-133b may be a useful therapeutic target
in CRC.10 M 60y C -
11 F 68y A* -
12 F 60y C -
13 M 48y C LN
14 M 74y C -
15 F 68y B -
16 M 68y C -
17 M 69y C LN
18 M 72y D* G*
19 M 65y B -
20 M 55y B -
21 F 61y B -
22 M 70y B -
23 F 85y A -
24 M 67y C LN
25 M 56y D L
26 M 56y D LN/L
27 M 65y D LMaterials and methods
Patients, tissues, cell lines and cultures
Thirty-one fresh, human CRC tissues and nineteen adja-
cent, non-tumor tissue counterparts (NTs) were obtained
from CRC patients at the time of surgery at the Southwest
Hospital Affiliated Third Military Medical University. The
tumor identity was verified by pathologists. All specimens
were snap-frozen in liquid nitrogen immediately after sur-
gery and then stored at −80°C until use. Detailed clinical
information for these patients is presented in Table 1. Tu-
mors were stratified according to the internationally ac-
cepted Modified Dukes Staging System, and the study was
approved by the local ethics committee. Written, informed
consent was obtained from all patients.
The HEK-293T and human CRC cell lines SW-480,
SW-620, HCT-15, HCT-116, Caco-2 and RKO were pur-
chased from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China), maintained in a 37°C humidi-
fied incubator, and cultured in appropriate media as rec-
ommended by the supplier.28 F 85y A -
29 M 65y C LN
30 M 55y C LN
31 M 42y D L
*F: female; M: male; A, B, C, D: Dukes A, B, C, D; -: no metastasis found;
LN: lymph node metastasis; L: liver metastasis.Plasmid construction
Wild-type and full-mutated miR-133b putative target
segments comprising 59 bp of the 3′UTR (untranslated
terminal region) of CXCR4 were synthesized by Invitrogen
(Invitrogen, China) and cloned into the psiCHECK-2-
CXCR4 vector (Promega, Madison, WI, USA) for miRNA
functional analysis. These plasmids were designated
psiCHECK-2-CXCR4 wt and psiCHECK-2-CXCR4 full
mut, respectively. The psiCHECK-2-CXCR4 full-mutated
vector introduced the full mutation into the miR-133b
binding sites of the CXCR4 3′UTR. Additionally, we
generated a luciferase vector containing the full length
3′UTR of CXCR4 by RT-PCR, and this was designated
as psiCHECK-2-CXCR4 full length. Proper insertion was
confirmed by sequencing, and all utilized primers are
described in Additional file 6: Table S1.Cell transfection
The following oligonucleotides were purchased from
GenePharma (GenePharma, Shanghai, China): miR-133b
mimics; miRNA negative control (designated as miR-NC);
miR-139 mimic as a positive control; miR-133b antisense
with a sequence complementary to the mature miR-133b;
and miRNA antisense negative control (designated as
inhibitor-NC), which is a negative control for miR-133b
antisense. The small interfering RNAs (siRNA) against
the human CXCR4 (GenBank Access. NM_001008540.1
and NM_003467.2) transcripts (denoted as siCXCR4)
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NC) were purchased from Guangzhou Ribo-Bio Co., Ltd
(Guangzhou, China). The sequence of siCXCR4 is de-
scribed in Additional file 6: Table S1. Lipofectamine
2000 (Invitrogen Corporation, Carlsbad, CA, USA) was
used for reverse transfection of the small molecules as
well as cotransfection of the miRNA mimics and reporter
vectors at optimized concentrations (10–200 nM) accord-
ing to the manufacturer’s recommendation. The plasmid
pcDNA-6.2 containing GFP was used as a positive control
for plasmid transfection, and Block it™ tagged with fluor-
escein was used as a positive control for oligonucleotide
transfection. Twenty-four to 60 hours after transfection,
the cells were harvested for the dual luciferase reporter
assay, protein analysis or RNA extraction.
Luciferase target assays
Once 70-80% confluent in 48-well plates, HEK-293T cells
were cotransfected with 50 ng/well of each luciferase
reporter plasmid and 10 nM/well of either miR-133b
mimic, miR-139 mimic or miR-NC, as described above.
The lysates were collected 36 hours posttransfection to
determine firefly and Renilla luciferase activity using
the Dual-Luciferase Assay Kit (Promega, Madison, WI)
following the manufacturer’s instructions. All experi-
ments were performed in triplicate.
Total RNA extraction and quantitative reverse
transcription-PCR (qRT-PCR) analysis
Total RNA was extracted from cells using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instructions. Tissue was porphyrized in liquid ni-
trogen, and then the RNA was extracted with TRIzol.
The expression of mature miR-133b was determined
using the Hairpin-it™ Assay kit (GenePharma, Shanghai,
China) and normalized to U6-snRNA. A qRT-PCR for the
CXCR4-mRNA was performed using the SYBR Premix
ExTaq real-time PCR kit (Takara, Japan) according to the
manufacturer’s instructions with GAPDH as the normal-
ization controls, respectively. Each reaction was carried
out in triplicate. To calculate the relative expression
levels, we used the 2-ΔΔCT-method. All primer sequences
can be observed in Additional file 6: Table S1.
Protein extraction, western blotting and antibodies
Specimens were preprocessed as mentioned above, and total
protein was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) as recommended. Protein samples
were lysed in buffer containing 1% DTT, 4% CHAPS,
7 M urea, 2 M thiourea and 2% ampholine. A volume
of extract equivalent to 15 μg of total protein was sepa-
rated in a 12% SDS-PAGE gel and then transferred to a
methanol-activated PVDF membrane (Millipore, Beijing,
China). The membranes were blocked with 5% BSA(bovine serum albumin, Sangon, Shanghai, China) and
then incubated with primary antibody that selectively
recognized CXCR4 (ab2074, Abcam, USA) at 4°C over-
night. To determine the amounts of loaded proteins,
membranes were also blotted with anti-GAPDH anti-
body (Proteintech Technology, Manchester, UK). Subse-
quently, we incubated the membranes with HRP-conjugated
secondary anti mouse (Pierce) or rabbit (Sigma-Aldrich)
antibody, and then protein bands were visualized by
adding ECL Plus Western blotting detection reagents
(Millipore) and exposure to Kodak film following the
manufacturer’s instructions. Protein levels were normal-
ized to GAPDH.
Cell proliferation and colony formation assays
Cell proliferation was assessed using the Cell Counting
Kit-8 (CCK-8, Dojindo Molecular Technologies, Shanghai,
China) as previously described. Cells were seeded as 5
replicates at a density of 6000/well in 100 μl of full
medium in 96-well plates and transfected with miR-133b
mimics (100 nM), miR-NC (100 nM), miR-133b inhibitor
(200 nM), inhibitor-NC (200 nM), siCXCR4 (120 nM) or
si-NC (120 nM) as described above. The cells were then
incubated at 37°C, and the absorbance was measured at
wavelengths of 480 nm and 630 nm on consecutive days
for four days.
For colony formation assays, 1000 cells that had been
transfected with oligonucleotides were suspended in 2 ml
of full medium and then seeded in 6-well plates. The
cells were washed with phosphate-buffered saline (PBS),
fixed with methanol and stained with crystal violet (0.1%
crystal violet in 20% methanol) after 12-day incubation.
Colonies with more than 50 cells were counted, and five
fields were counted for each plate. The assay was per-
formed in triplicate for each cell line.
Apoptosis assay (fluorescence-activated cell sorting
(FACS) analysis)
Cells were transfected with the small molecules for
48 hours followed by a 24-hour exposure to cisplatin at
final concentrations of 2.5 μg/ml and 1 μg/ml, respect-
ively. After trypsinization and washing with ice-cold PBS,
the cell suspensions were stained using Annexin V/FITC
and propidium iodide (PI) (Annexin V/PI Apoptosis De-
tection Kit, Lianke, China) and then analyzed by measur-
ing the membrane redistribution of phosphatidylserine by
flow cytometry (Beckman Coulter, USA). The experiments
were performed in triplicate.
Cell migration and invasion assays
Migration and invasion assays were conducted using
Transwell chambers (8 μm, Corning Costar Co., Cambridge,
MA) according to the manufacturer’s instructions. Briefly,
24 hours after transfection, the cells were starved for
Duan et al. Molecular Cancer 2013, 12:164 Page 11 of 12
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serum-free medium to a final concentration of 2 × 105/ml
(for the migration assays) or 4 × 105/ml (for the invasion
assays). The cell suspension (200 μl) was then pipetted
into the top chamber. Medium (600 μl) with 10% fetal
bovine serum was added to the lower chamber as a
chemoattractant. After 36-hour incubation, the cells on
the upper side of the membrane were mechanically re-
moved with cotton swabs, and cells that migrated to the
lower surface were fixed with 100% methanol and stained
with 0.1% crystal violet. The cells were counted in five
fields for triplicate membranes at 10× magnification using
a microscope (Zeiss).
Cell invasion assays were performed as described for the
cell migration assay, but polycarbonate membranes coated
with 45 μl of 300 μg/ml extracellular matrix (Matrigel; BD
Biosciences, San Jose, CA) that was diluted with medium
lacking FBS were used.Scratch wound healing assay
Transfected SW-480 and SW-620 cells were cultured in
24-well plates for 24–48 hours in standard conditions
until 70-80% confluency. Linear wound tracks were gener-
ated with sterile, 10-μl pipettes and maintained under
standard conditions. The scratched cells were then rinsed
twice with PBS to remove non-adherent cells, and fresh
culture medium was added. Photographs of the centers of
the gaps were taken using a phase-contrast microscope
and the same magnification, 100×. The cell migration at 0,
24, and 48 h after scratching was evaluated by determining
the wound distance at two random wound gap locations.
Three independent scratch-wound experiments were used
for calculations.Statistical analysis
All statistical calculations were performed using GraphPad
Prism (GraphPad Prism Software, Version 5.0, GraphPad,
San Diego, CA) and SPSS (Statistical Package for the
Social Scienes) PASW Statistics software (versions 17.0,
USA).
Fisher’s exact test and the Mann–Whitney U-test were
used to compare differences between two groups. The
related clinical data after logarithmic transformation were
used to analyze the diagnostic utility by receiver operating
characteristic (ROC) curves. Discriminant analysis was
conducted to find and build a model of predicted prob-
ability. The correlation between miR-133b and CXCR4
was determined by the Spearman rank correlation test.
Youden’s index was used to predict the optimal cutoff
point. The other data in each group were defined as the
mean ± SD. All p values were two-tailed, and p < 0.05
was considered statistically significant.Additional files
Additional file 1: Figure S1. Successful exogenous molecules
transfection was confirmed by qRT-PCR normalized to GAPDH/U6 snRNA
expression. Data are shown as the mean ± SD from three independent
assays. *P < 0.05 as compared with control.
Additional file 2: Figure S2. Expression of CXCR4 protein in 19 paired
CRC tissues was detected using a Western blot analysis normalized to
GAPDH in CRC samples. In 10 of 19 patients, the expression of miR-133b
in the tumors is higher than in the adjacent non-tumor tissues (signed
by star).
Additional file 3: Figure S3. The effect of miR-133b on CRC proliferation.
Additional file 4: Figure S4. Colony formation assay performed in
SW-620. The number of colonies was counted under a microscope
using an original magnification of 100× to adjust for the different density of
each cell line.
Additional file 5: Figure S5. (A) Observation of the apoptosis of SW-480
cells transfected with small molecules under a fluorescent microscopy.
(B) Observation of the apoptosis of SW-620 cells transfected with small
molecules under a microscopy. Original magnification: 200×.
Additional file 6: Table S1. Primers and siRNA sequences used in
this study.
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